KORU Medical Systems, Inc. (KRMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 6, 2025, announces the financial results for the second quarter ended June 30, 2025. The filing also includes updated financial guidance for the fiscal year ending December 31, 2025. A related conference call was scheduled for August 6, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
The Company highlights the use of the following non-GAAP financial measures to supplement GAAP results:
- Adjusted EBITDA: Defined as net income/loss before interest, depreciation, amortization, reorganization charges, and stock-based compensation.
- Adjusted Diluted EPS: Adjusted for interest, depreciation, amortization, and stock-based compensation to reflect ordinary operations.
Material Changes
The filing does not detail specific material changes versus prior periods. It notes that the Company has issued updated financial guidance for the full fiscal year 2025, but the specific nature of these changes is not described in the 8-K text itself.
Guidance, Outlook, and Risks
Guidance: The Company has updated its financial guidance for the fiscal year ended December 31, 2025. Specific targets are not listed in this document.
Management Commentary: Management utilizes adjusted EBITDA and adjusted diluted EPS as internal measures for planning, forecasting, and evaluating performance against expectations. They caution that these non-GAAP measures may differ from similar measures used by other companies and should not replace GAAP measures.
Risks and Contingencies: No specific new risks or contingencies are detailed in this filing text beyond the standard caution regarding the interpretation of non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net income, and cash flow figures.
- Verify the specific details of the updated full-year 2025 guidance referenced in the press release.
- Examine the reconciliation of GAAP to non-GAAP results provided in the press release to understand adjustments to EBITDA and EPS.
- Listen to the conference call recording (if available) for management's qualitative commentary on the results and outlook.